ACELYRIN (SLRN) 2024 Wells Fargo Healthcare Conference summary

Recent strategic changes and portfolio focus

• Leadership changes and strategic review led to deprioritization of internal development for HS and PsA, with a focus on lonigutamab for thyroid eye disease (TED).

• Positive clinical data in HS and PsA, but decision made to allocate resources to TED due to market and organizational fit.

• Company restructuring extended cash runway into mid-2027, fully funding pivotal TED programs.

Uveitis program and market opportunity

• Uveitis trial with izokibep completed enrollment and is fully funded; decisions on future development or partnering will follow data review.

• Rationale for IL-17 in uveitis based on strong preclinical and clinical data, aiming for efficacy comparable or superior to Humira.

• Study design mirrors VISUAL-1, with steroid taper and two arms: steroid only vs. izokibep plus steroid.

• Uveitis market in the US is significant, with potential for orphan pricing and a large unmet need.

• Data readout for uveitis expected by year-end.

Lonigutamab (TED) development and differentiation

• Lonigutamab positioned as a subcutaneous therapy for TED, aiming to shift the market from IV to subQ for greater convenience and home use.

• Molecule shows higher potency and lower exposure compared to competitors, with potential safety and efficacy advantages.

• Dose-ranging studies in phase 2 are designed to optimize efficacy and safety, with plans to start phase 3 in Q1 next year.

• Ongoing discussions with FDA will focus on dose selection, chronic dosing paradigm, and label requirements.

• Audiograms and MRIs are being used to monitor safety, particularly hearing impairment, with no current association seen with lonigutamab exposure.